Literature DB >> 12389824

COX-2 inhibitors in the treatment of cardiovascular disease.

John C Peterson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12389824      PMCID： PMC126485     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  9 in total

1.  Cardiovascular events and COX-2 inhibitors.

Authors:  E J Haldey; M Pappagallo
Journal:  JAMA       Date:  2001-12-12       Impact factor: 56.272

2.  Cardiovascular events and COX-2 inhibitors.

Authors:  W B White; A Whelton
Journal:  JAMA       Date:  2001-12-12       Impact factor: 56.272

3.  Cardiovascular events and COX-2 inhibitors.

Authors:  G Singh
Journal:  JAMA       Date:  2001-12-12       Impact factor: 56.272

4.  Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients.

Authors:  A Whelton; J G Fort; J A Puma; D Normandin; A E Bello; K M Verburg
Journal:  Am J Ther       Date:  2001 Mar-Apr       Impact factor: 2.688

5.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

Review 6.  Risk of cardiovascular events associated with selective COX-2 inhibitors.

Authors:  D Mukherjee; S E Nissen; E J Topol
Journal:  JAMA       Date:  2001 Aug 22-29       Impact factor: 56.272

7.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Authors:  C Bombardier; L Laine; A Reicin; D Shapiro; R Burgos-Vargas; B Davis; R Day; M B Ferraz; C J Hawkey; M C Hochberg; T K Kvien; T J Schnitzer
Journal:  N Engl J Med       Date:  2000-11-23       Impact factor: 91.245

8.  A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database.

Authors:  S Z Zhao; M W Reynolds; J Lejkowith; A Whelton; F M Arellano
Journal:  Clin Ther       Date:  2001-09       Impact factor: 3.393

9.  Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac.

Authors:  William B White; Gerald Faich; Andrew Whelton; Clement Maurath; Nancy J Ridge; Kenneth M Verburg; G Steven Geis; James B Lefkowith
Journal:  Am J Cardiol       Date:  2002-02-15       Impact factor: 2.778
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.